GILD
60
-3
STZ
55
2
HAS
33
-2
NOC
50
-7
FSLR
40
-3
WBA
48
-5
TSN
47
9
CME
61
2
MLM
60
-4
AEE
63
-3
AIZ
75
2
STI
12
-2
SYK
73
5
EQIX
60
-3
SHW
68
-5
RRC
63
-6
NI
70
-5
IFF
51
-3
AMG
38
-3
FOX
60
5
GILD
60
-3
STZ
55
2
HAS
33
-2
NOC
50
-7
FSLR
40
-3
WBA
48
-5
TSN
47
9
CME
61
2
MLM
60
-4
AEE
63
-3
AIZ
75
2
STI
12
-2
SYK
73
5
EQIX
60
-3
SHW
68
-5
RRC
63
-6
NI
70
-5
IFF
51
-3
AMG
38
-3
FOX
60
5
Financhill
Back

Allogene Therapeutics Quote, Financials, Valuation and Earnings

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.
Sell
30

ALLO
Allogene Therapeutics

Last Price:
2.73
Seasonality Move:
-6.71%

7 Day Trial

ALL ACCESS PASS

$ 7

"This Changes Everything" - Trump Hands Millions Massive IRS Gift

Learn More Here

Allogene Therapeutics Price Quote

$2.73
-0.11 (-3.87%)
(Updated: November 13, 2024 at 5:55 PM ET)

Allogene Therapeutics Key Stats

Sell
30
Allogene Therapeutics (ALLO) is a Sell
Day range:
$2.83 - $3.05
52-week range:
$2.01 - $5.78
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6,013.03
P/B ratio:
1.28%
Volume:
2.3M
Avg. volume:
2.1M
1-year change:
13.6%
Market cap:
$595.5M
Revenue:
$95K
EPS:
$-1.56

How Much Does Allogene Therapeutics Make?

Data Unavailable

Is Allogene Therapeutics Growing As A Company?

Data Unavailable

Allogene Therapeutics Stock Price Performance

What Is Allogene Therapeutics 52-Week High & Low?

Allogene Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Allogene Therapeutics?

Is Allogene Therapeutics Cash Flow Positive?

  • What Is ALLO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$217.3M
  • What Is Allogene Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $111.1M
  • What Is Allogene Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $88.2M

Allogene Therapeutics Return On Invested Capital

Data Unavailable

Allogene Therapeutics Earnings Date & Stock Price

Allogene Therapeutics Competitors

  • Who Are Allogene Therapeutics's Competitors?
    Below is a list of companies who compete with Allogene Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • ANI Pharmaceuticals Inc (ANIP)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Protalix BioTherapeutics Inc (PLX)

Allogene Therapeutics Dividend Yield

Allogene Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 17.77%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 9.25
Upside from Last Price: 225.7%

Major Shareholders

  • How many ALLO shares are owned by institutional investors?
    287.6M ALLO shares are owned by institutional investors
  • How many ALLO shares are owned by insiders?
    13.3M ALLO shares are owned by insiders